Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Prostate Cancer Diagnostics Monthly Minutes
Prostate Cancer Diagnostics
Diagnostic Capability in Relapsed Prostate Cancer Improved with ¹⁸F-DCFPyL PET/CT Imaging
Prostate Cancer Diagnostics
Web Exclusives
Recently released analysis of
18
F-DCFPyL PET/CT accuracy demonstrated improved diagnostic capability in men with biochemical recurrence of prostate cancer.
Read More
NaF PET Imaging Demonstrates Increased Sensitivity for New Lesion Detection for Patients with Metastatic Prostate Cancer
Prostate Cancer Diagnostics
Web Exclusives
NaF PET imaging study demonstrates an increased sensitivity over Tc99m-MDP bone scans for new lesion detection in patients with stable metastatic prostate cancer.
Read More
Recent Study Results Finds ¹⁸F-Fluciclovine PET/CT Alters Recurrent Prostate Cancer Management
Prostate Cancer Diagnostics
Web Exclusives
Salvage radiotherapy decisions for patients with recurrent prostate cancer after prostatectomy change after
18
F-fluciclovine PET/CT reveals higher positive findings than conventional imaging.
Read More
Multicenter International Prospective Trial on Gallium-68 PSMA PET/CT Imaging Confirms Accuracy in Detecting Prostate Cancer Recurrence
Prostate Cancer Diagnostics
Web Exclusives
Gallium-68 PSMA PET/CT imaging in patients with early relapsed prostate cancer confirms the reliability of this imaging modality in local and metastatic lesion detection.
Read More
Whole-Body MRI Found Superior to Bone Scan for Prognosis in Patients with Metastatic Prostate Cancer
Prostate Cancer Diagnostics
Web Exclusives
Recently released study results indicate whole-body MRI is superior to bone scan for prognosis in patients with metastatic hormone-naïve prostate cancer.
Read More
EMPIRE-1 Phase 2/3 Trial Results Indicate Fluorine 18 Fluciclovine PET/CT Utilization May Confer Event-Free Survival Advantage
Prostate Cancer Diagnostics
Web Exclusives
The recent release of EMPIRE-1 phase 2/3 trial results indicates the use of fluorine 18 fluciclovine PET/CT to guide salvage postprostatectomy radiotherapy increases event-free survival from biochemical recurrence or persistence.
Read More
Recent Review Article Highlights PSMA-Based Radioligands Diagnostic Value in Prostate Cancer
Prostate Cancer Diagnostics
Web Exclusives
Promising diagnostic and prognostic information with PSMA-based radioligands discussed in recently released review article.
Read More
Researchers Released Data from a Clinical Trial Investigating Fluorine 18 Fluciclovine PET/CT Use to Identify Targets for Site-Directed Therapy
Prostate Cancer Diagnostics
Web Exclusives
Investigators released participant group data from a clinical trial looking at the use of fluorine 18 fluciclovine PET/CT in men with prostate cancer and biochemical recurrence to identify potential targets for therapy.
Read More
Phase 3 INDICATE Trial Evaluating the Use of Apalutamide in Patients with Biochemical Recurrence of Prostate Cancer
Prostate Cancer Diagnostics
Web Exclusives
Updates on patient eligibility and methods from the INDICATE phase 3 trial were presented at the 2021 American Society of Clinical Oncology annual meeting.
Read More
Androgen Deprivation Therapy at Time of Fluorine 18 Fluciclovine PET/CT More Likely to Return a Positive Scan
Prostate Cancer Diagnostics
Web Exclusives
Real-world study suggests prostate-specific antigen levels, race, and the use of androgen deprivation therapy are predictors of a positive FACBC PET/CT scan.
Read More
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Perioperative Nivolumab Extends Event-Free Survival in Resectable NSCLC
William King
2.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
3.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma